TY - JOUR
T1 - Hypomagnesemia and survival in patients with head and neck cancers who received primary concurrent chemoradiation
AU - Liu, Wenli
AU - Qdaisat, Aiham
AU - Ferrarotto, Renata
AU - Fuller, Clifton D.
AU - Guo, Ming
AU - Meyer, Larissa A.
AU - Narayanan, Santhosshi
AU - Lopez, Gabriel
AU - Cohen, Lorenzo
AU - Bruera, Eduardo
AU - Hanna, Ehab Y.
AU - Yeung, Sai Ching J.
N1 - Funding Information:
The University of Texas MD Anderson Cancer Center is supported in part by the National Institutes of Health through Cancer Center Support Grant P30 CA016672.
Funding Information:
Renata Ferrarotto has acted as a paid member of the advisory board for Regeneron‐Sanofi; has acted as a paid member of the advisory board for, has received consulting fees from, and has received fees to her institution from Ayala Pharmaceuticals; has acted as a paid member of the advisory board for and received fees to her institution from Prelude Pharmaceuticals; has received consulting fees from Bicara; has acted as a paid member of the advisory board for and has received consulting fees from Klus Pharma; has received personal fees for an educational video from Medscape; has received consulting fees from Carevive; and has received fees to her institution from AstraZeneca, Merck, Genentech, and Pfizer for work performed outside of the current study. Larissa A. Meyer has received grants from the National Cancer Institute (grant K07CA20103), has received research support for unrelated research from AstraZeneca, and has acted as a paid member of the advisory board for GlaxoSmithKline for work performed outside of the current study. Eduardo Bruera has received grants to his institution from Helsinn Healthcare for work performed outside of the current study. Sai‐Ching J. Yeung has received grants from Depomed Inc and Bristol‐Myers Squibb and has received personal fees from Celgene Inc for work performed outside of the current study. The other authors made no disclosures.
Publisher Copyright:
© 2020 American Cancer Society
PY - 2021/2/15
Y1 - 2021/2/15
N2 - Background: Prior research has confirmed that persistent hypomagnesemia was predictive of shorter survival among patients with ovarian cancer who received carboplatin-based chemotherapy. In the current retrospective study, the authors examined the association between hypomagnesemia and survival in patients with head and neck cancer who received concurrent chemoradiation with weekly infusions of cisplatin and/or carboplatin. Methods: Patients with head and neck cancers who had undergone chemoradiation with cisplatin and/or carboplatin between January 1, 2010, and December 31, 2014, were included. Patients were aged ≥18 years with pathology of squamous cell carcinoma of the larynx, oral cavity, or oropharynx who had received at least 30 fractions of radiotherapy with concurrent weekly cisplatin and/or carboplatin. Pathology features, laboratory results, Eastern Cooperative Oncology Group performance status, social histories, and survival were recorded. The association between hypomagnesemia and survival was analyzed controlling for known prognostic factors. Results: The final cohort consisted of 439 patients with a median age of 59 years. A greater frequency of hypomagnesemia during the treatment course was found to be significantly associated with shorter survival (hazard ratio [HR], 1.13; P =.033) independent of age (HR, 1.65; P =.042), cancer site (nonoropharynx vs oropharynx: HR, 2.15 [P =.003]), Eastern Cooperative Oncology Group performance status (>1 vs ≤1: HR, 2.64 [P <.001]), and smoking history (smoker vs nonsmoker: HR, 1.88 [P =.012]). In addition, more severe hypomagnesemia was associated with shorter survival compared with the milder form. Conclusions: The frequency and severity of hypomagnesemia during treatment are prognostic of survival for patients with head and neck cancers who are receiving concurrent chemoradiation with cisplatin and/or carboplatin. A prospective study is needed to investigate the impact of the prevention of hypomagnesemia on survival in this patient population.
AB - Background: Prior research has confirmed that persistent hypomagnesemia was predictive of shorter survival among patients with ovarian cancer who received carboplatin-based chemotherapy. In the current retrospective study, the authors examined the association between hypomagnesemia and survival in patients with head and neck cancer who received concurrent chemoradiation with weekly infusions of cisplatin and/or carboplatin. Methods: Patients with head and neck cancers who had undergone chemoradiation with cisplatin and/or carboplatin between January 1, 2010, and December 31, 2014, were included. Patients were aged ≥18 years with pathology of squamous cell carcinoma of the larynx, oral cavity, or oropharynx who had received at least 30 fractions of radiotherapy with concurrent weekly cisplatin and/or carboplatin. Pathology features, laboratory results, Eastern Cooperative Oncology Group performance status, social histories, and survival were recorded. The association between hypomagnesemia and survival was analyzed controlling for known prognostic factors. Results: The final cohort consisted of 439 patients with a median age of 59 years. A greater frequency of hypomagnesemia during the treatment course was found to be significantly associated with shorter survival (hazard ratio [HR], 1.13; P =.033) independent of age (HR, 1.65; P =.042), cancer site (nonoropharynx vs oropharynx: HR, 2.15 [P =.003]), Eastern Cooperative Oncology Group performance status (>1 vs ≤1: HR, 2.64 [P <.001]), and smoking history (smoker vs nonsmoker: HR, 1.88 [P =.012]). In addition, more severe hypomagnesemia was associated with shorter survival compared with the milder form. Conclusions: The frequency and severity of hypomagnesemia during treatment are prognostic of survival for patients with head and neck cancers who are receiving concurrent chemoradiation with cisplatin and/or carboplatin. A prospective study is needed to investigate the impact of the prevention of hypomagnesemia on survival in this patient population.
KW - carboplatin
KW - cisplatin
KW - head and neck cancer
KW - hypomagnesemia
KW - radiotherapy
KW - survival
UR - http://www.scopus.com/inward/record.url?scp=85092901847&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85092901847&partnerID=8YFLogxK
U2 - 10.1002/cncr.33283
DO - 10.1002/cncr.33283
M3 - Article
C2 - 33085092
AN - SCOPUS:85092901847
SN - 0008-543X
VL - 127
SP - 528
EP - 534
JO - Cancer
JF - Cancer
IS - 4
ER -